RANKL is a therapeutic target of bone destruction in rheumatoid arthritis

Sakae Tanaka
  • F1000Research, April 2019, Faculty of 1000, Ltd.
  • DOI: 10.12688/f1000research.17296.1

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

open access logoRead Publication


The following have contributed to this page: Dr. Sakae Tanaka